Oncoinvent's normal tissue dosimetry results for Radspherin® in Journal of Nuclear Medicine reinforce its safety profile for ovarian and colorectal cancer therapies
Executive summary: Oncoinvent announced the publication of normal tissue dosimetry results from Phase 1 studies of Radspherin® in ovarian and colorectal cancer in the Journal of Nuclear Medicine on August 11, 2026. The results demonstrate that radiation exposure to healthy organs stays below levels linked to toxicity, validating the drug's safety profile and reducing a major barrier to clinical advancement.
Who is involved: Oncoinvent (developer of Radspherin®), researchers involved in the Phase 1 trials, and the Journal of Nuclear Medicine (publisher).
Likely next: Oncoinvent may proceed to Phase 2 trials or seek partnerships for further development, leveraging the published safety data to support regulatory engagement.
Oncoinvent has published clinical dosimetry data from Phase 1 trials of its radiopharmaceutical Radspherin® in the Journal of Nuclear Medicine, showing absorbed doses to normal organs remain below toxicity thresholds. The findings align with the previously observed favorable safety profile and support continued development of the treatment. This publication provides independent validation of the drug's tolerability, a critical factor for advancing toward later-stage trials and potential regulatory submission. The results address a key concern in radiopharmaceutical therapy: minimizing damage to healthy tissue while maintaining antitumor efficacy.
What's next — scenarios
Clinical Validation (Base Case) (60%)
Reduced regulatory risk and increased attractiveness for biotech partnerships/M&A.
- Peer-reviewed validation of dosimetry data
- No reported adverse safety events in expanded cohort
Expansion Potential (Upside) (25%)
Accelerated timeline for Phase 2 trials in additional solid tumor indications.
- Positive correlation between absorbed dose and tumor uptake
- Fast-track designation discussions
Efficacy Gap (Downside) (15%)
High safety profile fails to translate into therapeutic benefit, stalling clinical progression.
- Lower-than-expected tumor dose-response in upcoming data
- Competitive entry with superior therapeutic index
What to watch
- Next scheduled clinical readout for Phase 1 expansion (next 90 days)
- Oncoinvent investor relations updates regarding Phase 2 trial design (next 60 days)
- Peer citations or follow-up commentary in Nuclear Medicine journals (next 90 days)
Timeline
- — Oncoinvent announces publication of normal tissue dosimetry results in Journal of Nuclear Medicine (PR Newswire)
Analysis — what this means
Likely next events
- Oncoinvent to present updated Phase 1 safety data at the European Association of Nuclear Medicine congress in October 2026
- Potential initiation of Phase 2 trials for Radspherin® in ovarian cancer by Q1 2027
- Regulatory pre-submission meeting with the EMA expected in late 2026
- Publication of corresponding efficacy data from Phase 1 studies anticipated in Q4 2026
Sectors affected
- Radiopharmaceuticals
- Oncology therapeutics
- Nuclear medicine
- Biotechnology
Regulatory implications
- Favorable dosimetry supports alignment with FDA’s radiopharmaceutical safety guidance (2023) on organ dose limits
- Data may reduce non-clinical safety study requirements under ICH S9 for oncology therapeutics
- Supports compliance with EU Clinical Trials Regulation (CTR) dossier requirements for investigational radiopharmaceuticals
Historical parallels
- Similar safety validation for Lutathera® (2018) published in Journal of Nuclear Medicine preceded its FDA approval
- Pluvicto®’s normal tissue dosimetry results (2021) in the same journal supported its accelerated approval pathway
- Xofigo®’s bone marrow dosimetry data (2013) in Nuclear Medicine and Biology enabled its regulatory approval for metastatic prostate cancer